Novo Nordisk announced today that its blockbuster drug semaglutide failed to slow the progression of early-stage Alzheimer’s disease in two large-scale Phase 3 clinical trials, dealing a significant blow to hopes that the GLP-1 receptor agonist could treat neurodegenerative decline.
The Danish pharmaceutical company revealed that the twin trials, EVOKE and EVOKE+, did not meet their primary endpoint. The studies were designed to assess whether once-daily oral semaglutide (14 mg) could demonstrate superiority over a placebo in reducing disease progression, as measured by the Clinical Dementia Rating – Sum of Boxes (CDR-SB) score.
Trial Results and Data
The trials enrolled a combined total of 3,808 participants aged 55 to 85 who were diagnosed with mild cognitive impairment or mild dementia due to Alzheimer’s disease, with confirmed amyloid positivity. Over a 104-week main treatment period, patients received either the oral formulation of semaglutide—the active ingredient in the company’s diabetes and weight-loss drugs Ozempic, Rybelsus, and Wegovy—or a placebo.
While the treatment failed to provide a statistically significant clinical benefit in preserving cognitive function, Novo Nordisk noted that the drug did result in improvements in Alzheimer ’s-related biomarkers. However, these biological changes did not translate into a slowing of the patients’ cognitive decline.
The safety profile of oral semaglutide in the trials was consistent with its known effects in type 2 diabetes and obesity, appearing safe and well-tolerated by the elderly participant pool.
Based on the significant unmet need in Alzheimer’s disease as well as a number of indicative data points, we felt we had a responsibility to explore semaglutide’s potential, despite a low likelihood of success,
We are proud to have conducted two well-controlled Phase 3 trials in Alzheimer’s disease that meet the highest standards of research and rigorous methodology,
While semaglutide did not demonstrate efficacy in slowing the progression of Alzheimer’s disease, the extensive body of evidence supporting semaglutide continues to provide benefits for individuals with type 2 diabetes, obesity, and related comorbidities.
Martin Holst Lange
Market Impact and Strategic Context
The news triggered a sharp decline in Novo Nordisk’s stock, which fell approximately 9% to 12% following the announcement. Investors had viewed the Alzheimer’s program as a “lottery ticket”— a high-risk, high-reward opportunity that could have opened a massive new market for the company’s GLP-1 franchise.
Broader Implications for Alzheimer’s Research
The EVOKE trials were closely watched by the scientific community as a test of the “metabolic hypothesis” of Alzheimer’s disease. Previous research had suggested that GLP-1 receptor agonists might reduce neuroinflammation and improve brain energy metabolism, potentially offering a different mechanism of action than the anti-amyloid antibodies currently entering the market.
Last Modified:
